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A Mechanism of Cyclin D1 Action Encoded
in the Patterns of Gene Expression
in Human Cancer
dent at the earliest stages in the natural history of the
disease (Rosenberg et al., 1991; Vos et al., 1999). This
indicates that cyclin D1 overexpression likely also con-
tributes materially to the development of human cancer.
Numerous lines of investigation have identified a
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The population of genes whose levels were highly (3-
fold change), persistently, and reproducibly affected by
cyclin D1 overexpression were identified (Figure 2B).
Many of the changes in transcript level were apparent
soon after the transduced cyclin D1 protein was detect-
able, and these likely represent a direct effect of cyclin
D1 on transcription. Consistent with this, the promoter
of one of these genes (HSP70-2) has been shown by
others to be specifically activated by cyclin D1 (Kamano
and Klempnauer, 1997). Recovery of this known cyclin
D1 target gene provided a validation of both the selected
experimental conditions and filtering criteria.
The Cyclin D1 Expression Signature
as Functional Assay: The Relative Importance
of cdk-Dependent and -Independent Actions
To establish the requirement for cdk activation in the
Figure 1. Proposed Biochemical Functions of Cyclin D1
functional consequences of cyclin D1 overexpression,
(A) Cyclin D1 (or cyclin D2 or D3) activates cdk4 (or cdk6).
we examined the ability of a cyclin D1 mutant (K112E)(B) The cyclin D1 (or D2, D3) -cdk4 (-cdk6) complex exerts a noncata-
unable to activate cdk4 (Hinds et al., 1994) to recapitu-lytic activity.
late the wild-type cyclin D1 expression signature. Re-(C) Cyclin D1 modulates the activity of various transcription factors
(TF) without the participation of cdks. markably, the expression of all sixteen genes populating
See text for details and references. this signature was also markedly and reproducibly in-
duced by the KE mutant (Figure 2C). We then applied
our primary gene selection method to the data collecteddium approach so successful in yeast (Hughes et al.,
following transduction of this mutant protein. Thirteen2000). An obvious limitation to this, though, is the lack of
genes were recovered, of which eight were among thosea comprehensive collection of human reference profiles.
already identified as targets of wild-type cyclin D1. AndHowever, it is conceivable that the natural diversity of
although the expression characteristics of the remaindergenetic alterations in human cancer could be exploited
had not satisfied our stringent selection criteria, all fiveinstead to reveal the patterns of gene expression corre-
of these genes were also markedly affected by the wild-sponding to perturbation of many different genes. Of
type protein (Figure 2D). Thus, all 21 genes identifiedcourse, the expression profile of a single human tumor
were induced by both wild-type and mutant cyclin D1.specimen is likely to be an admixture of the transcrip-
These were taken as the definitive cyclin D1 expressiontional changes reflective of many unknown genetic
signature for the remainder of the study. Ribonucleasechanges. But given a sufficient number of expression
protection assays (RPA) with independently isolatedprofiles from tumors of various organs, it is conceivable
RNA confirmed the effects of cyclin D1 and cyclin D1-that these composite signatures could be deconvoluted
KE on eight of eleven target genes tested (Figure 2E).to form a virtual compendium of cancer-specific refer-
Similar results were obtained in the MDA-MB468 humanence profiles.
breast cancer cell line (data not shown). Taken together,Here we present a functional dissection of the mecha-
these data suggest that the effects of cyclin D1 overex-nism of cyclin D1 action based upon the use of gene
pression observed do not depend upon cdk4.expression profiling as a global assay for the effects of
cyclin D1 overexpression, and describe how the analysis
of human tumor gene expression data led to the identifi- Cyclin D1 Activity in Human Tumors
It is conceivable that the expression signature describedcation of C/EBP as a principal effector of cyclin D1
activity in human cancer. above, and the putatively cdk-independent function of
cyclin D1 encoded within it, is unique to the experimental
cell culture system in which it was defined and not repre-Results
sentative of the activities of cyclin D1 in cancer. To
address this issue, we turned to a database of geneA Molecular Phenotype for Cyclin
D1 Overexpression expression profiles from 190 primary human tumors of
14 different histological types, referred to as the GlobalRecombinant adenoviruses were used to ectopically ex-
press cyclin D1, a cyclin D1 mutant (see below), and Cancer Map (GCM) (Ramaswamy et al., 2001), reasoning
that biologically relevant cyclin D1 target genes wouldgreen fluorescent protein (GFP) as a control, in cycling
MCF-7 human mammary epithelial cells. Ectopic wild- be frequently coexpressed with endogenous cyclin D1
in these specimens. First, we constructed a list of thetype and mutant cyclin D1 were detectable 6 hr after
infection and were expressed at similar levels (Figure genes analyzed in the GCM ordered according to how
closely their expression pattern across all 190 tumors2A). No alterations in proliferation, cell cycle phase dis-
tribution, cell morphology, or cell death were discern- approximated that of cyclin D1 (Supplemental Data,
Section 1, at http://www.cell.com/cgi/content/full/114/ible. RNA was isolated at various times (0–24 hr) after
infection in two independent experiments, biotin-labeled, 3/323/DC1). We next used the Kolmogorov-Smirnov (KS)
nonparametric rank statistic (Hollander and Wolfe, 1999)and hybridized to microarrays composed of around
7,000 unique oligonucleotide probe-sets, henceforth re- to capture the position of the set of 21 genes identified
in vitro within this ordered list; the statistic is large whenferred to as genes.
C/EBP Is an Effector of Cyclin D1 Action
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Figure 2. Cyclin D1 Expression Signature
(A) Expression of wild-type and mutant cyclin
D1 proteins at various times following infec-
tion with recombinant adenoviruses revealed
by immunoblotting. Cellular proteins and
RNA used for microarray analysis were iso-
lated from parallel cultures.
(B) Temporal expression profiles of cyclin D1
target genes following transduction of GFP
or cyclin D1.
(C) Expression profiles of cyclin D1 target
genes following transduction of cyclin D1-KE.
(D) Expression profiles of target genes identi-
fied by overexpression of cyclin D1-KE.
Genes were selected by Method A, as de-
scribed in Experimental Procedures. Each
square of the colorgram represents the aver-
age of the normalized expression levels of the
specified gene at the indicated time, derived
from two independent experiments. Red
shading indicates high expression and blue
shading indicates low expression.
(E) Confirmation of selected cyclin D1 target
genes. Levels of the indicated transcripts in
total RNA isolated from MCF-7 cells infected
with adenoviruses 24 hr earlier were deter-
mined by ribonuclease protection assay.
many targets appear early in the list. Finally, the signifi- now been defined in an independent microarray experi-
ment (Ishida et al., 2001). KS analysis also allowed uscance of the observation was tested by calculating the
frequency at which the statistic on the target gene set to explore the relationship between cyclin D1 levels and
E2F-mediated transcription in human tumors. We foundwas equaled or exceeded in 100,000 trials with 21 genes
selected at random from the dataset. that a published set of E2F target genes (Ishida et al.,
2001) was not correlated with cyclin D1 in the GCM (pUsing this method, we determined that the expression
patterns of our set of target genes were indeed signifi- 0.668) (Figure 3C). In contrast, these E2F target genes
were highly correlated with cyclin D3 expression acrosscantly correlated with the levels of cyclin D1 in human
tumors (p  0.048). The appearance of most of the tar- the GCM (p  0.002). This not only provided verification
of the E2F target gene set, but also highlights a strikinggets early in the ordered list, and how this contributes
to a high KS score, is evident from a graphical represen- difference between two D-type cyclins considered to
exert similar if not identical biochemical activities, fur-tation of the analysis (Figure 3A). The correlation be-
tween the levels of cyclin D1 and our set of target genes ther reinforcing the notion that cyclin D1 possesses
unique mechanisms of action in human cancer.detected by KS analysis can be appreciated by compar-
ing the pattern of cyclin D1 expression across the entire
GCM with those of individual targets (Figure 3B). Thus, Discovering Participants in the Mechanism
of Cyclin D1 Action: Mining Tumor GeneKS analysis provided evidence that the expression sig-
nature identified in vitro had successfully captured a Expression Data
The KS metric was used as a data-exploration tool tofunction of cyclin D1 in vivo, supporting the existence
of a cdk-independent activity for cyclin D1 in human compute the degree of coexpression between the genes
of the cyclin D1 expression signature and each of thecancer.
No E2F target genes were found among those affected more than 16,000 genes in the GCM. These genes were
then ranked by KS score to highlight those with the mostby overexpression of wild-type or mutant cyclin D1 in
vitro (Figure 2), despite the fact that this gene set has propitious expression characteristics. A schema of the
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expression matches an aggregate of those of the genes
comprising the cyclin D1 signature can be appreciated
by comparing the expression patterns of the 50 genes
ranked highest by KSS (Figure 4B; see Supplemental
Data, Section 2) with those of the 21 gene query set
(Figure 4C).
As anticipated, cyclin D1 was ranked very highly by
KSS, being found at position 26 in an ordered list of
16,063 genes. This demonstrates that our analytical
method can successfully prioritize a gene whose protein
product participates directly in the transcriptional re-
sponse encoded in the query, and suggests that the list
shown in Figure 4B is enriched with such genes. Among
the other genes ranked in the top 50 by KSS were at
least eight encoding luminal epithelial cell markers (Fig-
ure 4B). Since the majority of solid tumors overexpress-
ing cyclin D1 are of luminal epithelial origin, this also
implies that our expression signature had captured the
function of cyclin D1 in the most biologically relevant
cell-type.
The rapidity of some of the changes in gene expres-
sion seen following ectopic overexpression of cyclin D1
in vitro (Figure 2) suggested the direct involvement of a
transcription factor in the mechanism of cyclin D1 ac-
tion. Three transcription factor genes—ESE-1b, BTEB2,
and C/EBP—were identified (www.geneontology.org)
among the 50 genes ranked highest by KSS with the
GCM (Figure 4B). Independent support for their candida-
ture as mediators of cyclin D1 action was sought in
secondary screens with a number of smaller publicly
available tissue-restricted tumor gene expression data-
bases. KSS was therefore performed with the cyclin D1
expression signature query in databases composed of
the expression profiles from 52 prostate (Singh et al.,
2002), 186 lung (Bhattacharjee et al., 2001), and 86 brain
tumors (Pomeroy et al., 2002), as well as the cell lines
of the NCI60 (Staunton et al., 2001) (Supplemental Data,
Sections 3–6).
These analyses (Table 1) revealed a consistently high
ranking for C/EBP, but neither BTEB2 nor ESE-1b, inFigure 3. Cyclin D1 Expression Signature in Human Tumors
the prostate, lung, and NCI60 databases. In contrast,(A) Kolmogorov-Smirnov analysis for the cyclin D1 target gene set.
none of the three transcription factor genes had a highThe running sum of consecutive values of the vector V at each
relative score in the brain tumor database, likely re-gene in the list of genes ordered according to the similarity of their
expression pattern to that of cyclin D1 across the GCM was plotted flecting the fact that these tumors are of nonepithelial
for the cyclin D1 target gene set. The statistic S for the association origin while the query signature represents an epithelial-
test is indicated. Accession numbers indicate the position of cyclin specific function of cyclin D1. Notwithstanding, the con-
D1 target genes in the GCM-derived gene list. The expression pat-
sistent coexpression of C/EBP with the genes of thetern of a gene placed high in this ordered list (toward the left) is
cyclin D1 expression signature across more than 500more similar to that of cyclin D1 than one placed beneath it (toward
human tumor specimens and cell lines from multiplethe right).
(B) Expression level correlation. The normalized expression level of independent databases strongly suggested the hypoth-
cyclin D1 and the indicated cyclin D1 target genes in each tumor esis that C/EBP is involved in regulating genes affected
specimen in the GCM was plotted. Tumor classes are identified as by cyclin D1 overexpression, and is therefore likely a
follows: BL, bladder transitional cell carcinoma; BR, breast adeno-
principal participant in a previously unappreciatedcarcinoma; CNS, central nervous system; CR, colorectal adenocar-
mechanism of cyclin D1 action.cinoma; LE, leukemia; LU, lung adenocarcinoma; LY, lymphoma;
ML, melanoma; ME, pleural mesothelioma; OV, ovarian adenocarci-
noma; PA, pancreatic adenocarcinoma; PR, prostate adenocarci- Data-Mining Validation: Function Analysis
noma; RE, renal cell carcinoma; UT, uterine. of Target Gene Promoters
(C) Kolmogorov-Smirnov analysis for the E2F target gene set. As
In an attempt to provide direct and independent evi-(A), except that the E2F target gene set was analyzed.
dence for the involvement of C/EBP in the mechanism
of cyclin D1 action, we conducted functional analyses
of the promoters of genes affected by cyclin D1 overex-data-mining process, which we refer to as Kolmogorov-
Smirnov Scanning (KSS), is provided as Figure 4A. The pression. To avoid potential bias introduced by examin-
ing only those genes used to generate the hypothesis,success of KSS in identifying genes whose pattern of
C/EBP Is an Effector of Cyclin D1 Action
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Figure 4. Kolmogorov-Smirnov Scanning
(A) Data-mining schema. A nearest neighbors (nn) list is constructed for each of the i genes in a database. The representation of the query
signature in each list is computed using the KS metric to give a score S for each gene. Genes are then ordered by descending score.
(B) The 50 genes ranked highest by KSS of the GCM with the cyclin D1 expression signature, and their pattern of expression across the GCM.
Cyclin D1 is highlighted in red, the three highest ranked transcription factor genes in blue, and luminal epithelial marker genes in bold.
(C) Expression pattern of the 21 genes of the cyclin D1 expression signature across the GCM.
Each square of the colorgrams represents the normalized expression level of the specified gene in a single tumor. Red shading indicates
high expression and blue shading indicates low expression. Tumor classes are identified as in Figure 3B.
we first returned to our original microarray data to define scripts feature AU-rich degradation signals in their 3
untranslated regions (Gaugitsch et al., 1992; Ubeda etan alternative cyclin D1 expression signature. The tran-
script levels of the HSP70-2 gene were affected within al., 1999) and are likely not transcriptionally regulated.
DRAL was also excluded by our failure to localize its2 hr of ectopic wild-type and mutant cyclin D1 being
detected (Figures 2A–2C), and its promoter has already promoter, and since the regulatory sequences of the
two HSP70 genes are90% identical (see Supplementalbeen shown to be specifically activated by cyclin D1
(Kamano and Klempnauer, 1997). We therefore took this Data, Section 7), the HSP70-1 promoter was not consid-
ered further. The promoter regions of the remaininggene as a template and selected the ten genes whose
temporal expression pattern most closely resembled seven genes were cloned upstream of a luciferase cDNA
and their responsiveness to cyclin D1 examined bythat of HSP70-2 across both independent in vitro experi-
ments (Figure 5A). Only three of these ten genes were transfection experiments in MCF-7 cells. Immunoblot
analyses confirmed that these cells express C/EBP,found in the primary expression signature. Nevertheless,
the effects of cyclin D1 and cyclin D1-KE on the expres- although shorter isoforms were undetectable (data not
shown). Only the cyclophilin 40 promoter constructsion of those identified here could be confirmed by RPA
(Figure 5B). These genes thus provided an independent failed to respond robustly. The other six reporters were
activated by cyclin D1 between 2- to 10-fold; the effectscyclin D1 target gene set for validation studies.
E16 and methionyl-tRNA synthetase (metRS) were ex- of cyclin D1 and cyclin D1-KE were largely indistinguish-
able (Figures 6A, 6D, and 6E, and data not shown).cluded from the promoter analysis because their tran-
Cell
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ure 6C). Oligonucleotides representing a number of theTable 1. Summary of KSS Results from Five Independent Gene
natural response elements, but not motifs mutated toExpression Databases
abolish cyclin D1 responsiveness in the context of a
Relative Position
reporter assay, also competed the formation of this
complex (Figure 6C). These findings thus reveal a corre-Database C/EBP BTEB2 ESE-1b
lation between the formation of a DNA-protein complexGCM 0.002 0.001 0.001
containing C/EBP and the responsiveness of a pro-Prostate 0.032 0.689 0.253
moter to cyclin D1.Lung 0.034 0.076 0.196
Brain 0.210 0.559 0.635 We next examined whether C/EBP was involved in
NCI60 0.015 0.246 0.188 regulating our panel of promoters by cotransfecting
each reporter construct with plasmids directing expres-KSS was performed with the 21 gene cyclin D1 expression signature
in each of the five listed databases. The relative positions of the sion of either wild-type or dominant-negative mutant
three transcription factor genes identified in the primary screen with C/EBP (C/EBPSpl) (Tsukada et al., 1994). The wild-
the GCM for each analysis are shown. Relative position is defined type protein had only a minimal effect on basal promoter
as rank position divided by the total number of genes in the data-
activity, but reduced increases induced by cyclin D1base. The databases have been described (Bhattacharjee et al.,
(Figure 6D). On the other hand, all of the cyclin D1-2001; Ramaswamy et al., 2001; Staunton et al., 2001; Pomeroy et
al., 2002; Singh et al., 2002). Complete KSS results are provided as responsive promoters tested were activated by C/EBP
Supplemental Data, Sections 2–6. Spl to a degree comparable with cyclin D1 itself (Fig-
ure 6A). Remarkably, promoters rendered refractory to
cyclin D1 by deletion or mutation were also unrespon-
sive to C/EBPSpl, and showed somewhat higherMapping the sites of cyclin D1 responsiveness by
basal activity than their respective wild-type counter-nested deletion and point mutation (Figure 6A) identified
parts (Figure 6A). Together, these data indicate that en-motifs with remarkable sequence similarity (Figure 6B).
dogenous C/EBP acts as a constitutive repressor ofThese elements also exhibited strong similarity to the
cyclin D1 target gene promoters and thereby providescore of the consensus C/EBP recognition site (T[G/T]
independent functional confirmation of the predictionNNG[A/C]AA[G/T]) (V$CEBPB_01; M00109; TRANSFAC).
made in silico that C/EBP is involved in the regulationConsistent with this, electrophoretic mobility shift
of genes whose transcription is affected by cyclin D1assays showed that such promoter elements formed
overexpression.a DNA-protein complex when incubated with MCF-7
But our functional and biochemical analyses had alsonuclear extracts that could be competed with C/EBP
antibodies, but not control (i.e., STAT3) antibodies (Fig- revealed the influence of cyclin D1 and C/EBP to be
Figure 5. An Alternative Cyclin D1 Expression Signature
(A) Temporal expression profiles of cyclin D1 target genes following transduction of GFP, cyclin D1, or cyclin D1-KE. Genes were selected
by Method B, as described in Experimental Procedures. Each square of the colorgram represents the normalized expression level of the
specified gene at the indicated time in the indicated independent experiment. Red shading indicates high expression and blue shading
indicates low expression.
(B) Confirmation of selected cyclin D1 target genes, as in Figure 2E. Results for some genes from this set are shown in Figure 2E.
C/EBP Is an Effector of Cyclin D1 Action
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exerted through the same sequence elements, indicat- expression in human tissues. Representing the actions
of oncogenes in this broad and systematic way provokesing that the transcriptional effects of cyclin D1 are likely
directly mediated by C/EBP. We therefore tested new approaches to dissecting their mechanisms of ac-
tion. Specifically, this digitization of functional informa-whether ablation of C/EBP function would negate the
ability of cyclin D1 to activate otherwise responsive pro- tion affords the opportunity for matching these patterns
of endogenous gene expression against the compositemoters. First, MCF-7 cells were cotransfected with each
of our reporter constructs, a cyclin D1 plasmid, and molecular phenotypes entrained within expression data
from human cancers, allowing hypotheses upon thevarying amounts of a plasmid directing expression of
dominant-negative C/EBP. These experiments showed pathways of oncogenesis to be built and tested, not
with abstracted in vitro or animal models, but in actualthat cyclin D1 was indeed unable to increase the activity
of any of the promoters tested when expressed together human tumors—in situ.
with higher levels of C/EBPSpl (Figure 6E). Second,
we made use of an epithelial cell line derived from the Mechanisms of Action of Cyclin D1
mammary glands of C/EBP nullizygous mice. And al- in Human Tumors
though ectopic overexpression of cyclin D1 increased It has been assumed that the established ability of cyclin
the activity of a cotransfected reporter construct in the D1 to activate cdk4/6, leading to phosphorylation of pRb
normal murine mammary epithelial cell line SCp2 (Des- with consequent derepression of E2F-mediated tran-
prez et al., 1993)—just as was seen in MCF-7 cells (Fig- scription (see Introduction), and the resulting promotion
ure 6A)—as anticipated, cyclin D1 had no effect on this of cell cycle progression, underlies the tumorigenic con-
reporter in C/EBP-deficient cells (Figure 6F). Taken sequences of cyclin D1 overexpression. However, con-
together, these data demonstrate that C/EBP is a criti- ventional analyses of human tumor material have fre-
cal effector of cyclin D1 action, and thereby confirm quently failed to find correlative evidence in support of
the existence of a functional interdependency between this model. For example, breast cancers overexpressing
cyclin D1 and C/EBP for gene transcription. cyclin D1 do not show correspondingly high levels of
During the course of these experiments, we learned the canonical E2F target gene cyclin E (Zukerberg et al.,
that C/EBP had been identified as one of the factors 1995) and exhibit relatively normal rates of proliferation
responsible for transcriptional regulation of the aspara- (Oyama et al., 1998). Similarly, hyperphosphorylation of
gine synthetase (AS) gene (Siu et al., 2001). AS was pRb is not observed in B cell lymphomas overexpressing
among the 21 genes defining our primary cyclin D1 ex- cyclin D1 (Zukerberg et al., 1996). Such data have led
pression signature (Figure 2), so we asked whether the some to suggest that the oncogenic activity of cyclin
same mutations in the AS promoter shown to abolish D1 must be exerted through pathways other than cdk-
C/EBP binding (Siu et al., 2001) also affected its re- dependent and E2F-mediated acceleration of the cell
sponsiveness to cyclin D1 overexpression. As antici- cycle (Weinstat-Saslow et al., 1995; Oyama et al., 1998).
pated, while the wild-type promoter was activated by The similarity of the transcriptional consequences of
cyclin D1 and cyclin D1-KE, the mutant promoter was ectopic overexpression of cyclin D1 and the cyclin D1
not (Figure 6G). This finding, when taken together with KE mutant, the paucity of E2F target genes in this cyclin
the published report, not only provides additional inde- D1 expression signature, and the absence of a correla-
pendent verification of an involvement of C/EBP in tion between the expression patterns of these E2F target
cyclin D1 function, but also indicates that this is likely not genes and cyclin D1 in the GCM argued directly against
restricted to the small subset of cyclin D1-responsive activation of cdk4 or sequestration of cdk inhibitor pro-
genes whose promoters were analyzed here. teins by catalytically inactive cyclin D1/cdk4 complexes
Finally, we investigated whether the functional inter- as the mechanism of cyclin D1 action in human tumors.
dependency between cyclin D1 and C/EBP might be It is of course conceivable that a single gene induced
attributable to a physical interaction between these two by a cdk-dependent action of cyclin D1 only modestly,
proteins. We found that cyclin D1 was efficiently coim- or not represented on our microarray, is the sole effector
munoprecipitated with C/EBP from the lysates of MCF- of cyclin D1-mediated oncogenesis. Equally, since our
7 cells cotransfected with plasmids directing expression cyclin D1 expression signature was established by ec-
of these proteins, but was undetectable in C/EBP im- topic overexpression in a cell culture system, the fidelity
munecomplexes (Figure 6H). These data indicate that of this gene set and our conclusion that these changes
cyclin D1 can indeed be found specifically in complexes are truly cdk-independent are not, when taken in isola-
containing C/EBP, not only providing an additional tion, beyond reproach. However, the remarkable consis-
layer of evidence in support of an operational connec- tency with which our set of target genes is found coex-
tion between these proteins but also suggestive of a pressed with cyclin D1 in human tumor specimens
model of cyclin D1 function based upon physical contact would appear to make the irrelevance of the mechanism
with C/EBP. it represents to the malignant phenotype unlikely.
We therefore developed a data-mining strategy (KSS)
to exploit our experimentally determined expression sig-Discussion
nature for the identification of potential participants in
the mechanism of cyclin D1 oncogenicity ab initio. AWe have employed gene expression profiling to estab-
lish the molecular phenotype of cyclin D1 overexpres- transcription factor previously unconnected with cyclin
D1 was ranked very highly by KSS across a number ofsion in a human cell line and used this empirically deter-
mined expression signature to study the mechanistic independent tumor gene expression databases. Subse-
quent functional analyses confirmed that C/EBP wasbasis of the oncogenic consequences of cyclin D1 over-
Cell
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Figure 6. Cyclin D1 and C/EBP Operate Together
(A) Promoter analysis. MCF-7 cells were cotransfected with a reporter construct and either an empty vector or a plasmid directing the
expression of cyclin D1-KE or C/EBPSpl. Normalized promoter activity was determined 24 hr later. Each square represents results for a
single reporter. The bottom segment identifies the promoter fragment by code number (Supplemental Data, Section 7) and the basal activity
of the promoter relative to pGL3-basic. The top left and right quadrants represent fold increases in promoter activity relative to empty vector
induced by cyclin D1-KE and C/EBPSpl, respectively. Crosses indicate the position of introduced mutations. Results are means of at least
two independent experiments each with triplicate determinations.
(B) Cyclin D1 response elements. Sequence elements conferring responsiveness to cyclin D1 identified by deletion and mutation analysis are
represented in (A).
(C) Formation of DNA-protein complexes with a cyclin D1 response element. Electrophoretic mobility shift assays were performed with nuclear
extracts from MCF-7 cells and a radiolabeled double-stranded DNA probe containing the cyclin D1 response element from the KIAA0201
promoter. Unlabeled double-stranded DNA probes (Supplemental Data, Section 8) or antibodies were added, as indicated.
(D) Ectopic expression of C/EBP negates the effects of cyclin D1 on promoter activity. MCF-7 cells were cotransfected with a reporter
construct, an empty vector, or plasmids directing expression of cyclin D1 or cyclin D1-KE, and either a C/EBP expression plasmid or empty
vector. Normalized promoter activity was determined 24 hr later and fold increases in promoter activity relative to empty vector were calculated.
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indeed a direct effector of the activity of cyclin D1 en- kada et al., 1994)—to recapitulate the effects of cyclin
D1 in our experiments suggests, then, that cyclin D1coded in its expression signature. These findings indi-
cate that the pathways connecting cyclin D1 with E2F- overexpression might likewise provide an alternative to
elevated levels of LIP as an underlying cause of disrup-mediated transcription are perhaps not so germane as
previously thought and instead implicate modulation of tion of C/EBP signaling in vivo.
C/EBP function as a major mechanism of cyclin D1
action in human cancer. Integrating Experimental and Tumor
Expression Data
The application of transcriptional profiling technologyCyclin D1 and C/EBP
to the analysis of individual oncogenes and their mecha-C/EBP—also known as Nf-Il6 or LAP—is a transcription
nisms of action in vitro has been hampered by concernsfactor of the basic leucine zipper family originally cloned
that effects seen in cell culture are not pathologicallyas a mediator of IL-6 signaling, now known to have
relevant. We dealt with this problem by developing aessential roles in a diversity of physiological processes
general method based upon the well-known Kolmo-and to regulate the normal differentiation and function
gorov-Smirnov statistic (Hollander and Wolfe, 1999) thatof a variety of tissues through both positive and negative
uses the patterns of gene expression in human canceraffects on gene transcription (Lekstrom-Himes and Xan-
to test the veracity of target gene sets derived fromthopoulos, 1998). Our data reveal that C/EBP is a con-
directed cell culture experiments.stitutive repressor of cyclin D1 target genes, and that
We also found that the integration of expression datacyclin D1 acts by antagonizing this repressor function.
from tumors and directed in vitro experiments could beDisruption of signaling through C/EBP has already
used for discovery. Rapidly expanding repositories ofbeen shown to contribute to malignant transformation.
tumor gene expression data contain a vast amount ofA single transcript encodes at least two distinct C/EBP
information about the processes of human cancer. How-isoforms from different in-frame translation start sites.
ever, this has remained largely untapped because theseBoth proteins share the DNA binding domain and leu-
are intrinsically static resources. So although groups ofcine-rich zipper dimerization helix, but the shorter of the
coexpressed genes can be identified, the interdepen-two—known as LIP—lacks most of the transactivation
dencies most informative for mechanistic understandingdomain, and although able to dimerize and bind to DNA,
(i.e. upstream-downstream relationships) cannot be dis-cannot activate transcription (Descombes and Schibler,
criminated from less incisive connections. Conversely,1991). The so-called LAP/LIP ratio appears to be tightly
in vitro expression profiling efforts deal exclusively inregulated and is increased greatly during terminal differ-
dynamic information; the primary upstream effector isentiation in a number of tissues (e.g., Descombes and
chosen and the downstream targets are identified. BySchibler, 1991; Raught et al., 1995). However, marked
constructing hierarchies with respect to such experi-decreases in this ratio resulting from aberrant overex-
mentally determined expression signatures, KSS solvespression of LIP have been observed in human breast
the problem of how to bring a dynamic query to a statictumors (Zahnow et al., 1997), and LIP levels are also
resource and reveal potential serial relationships en-greatly elevated in mouse mammary tumors (Raught et
crypted within human tumor gene expression databases.al., 1996). Indeed, enforced expression of a LIP trans-
gene in the murine mammary gland has been shown to
Experimental Procedureslead to the formation of invasive carcinomas (Zahnow
et al., 2001), all of which suggests that antagonism of Adenoviruses, Cells, and RNA
C/EBP function by LIP is an oncogenic event. The abil- Human cyclin D1 and cyclin D1-KE cDNAs were subcloned to pShut-
tle-CMV (a gift from Bert Vogelstein) and recombinant adenovirusesity of C/EBPSpl—the experimental analog of LIP (Tsu-
Data shown are for the IEF SSP 3521 promoter (code 197) but are qualitatively representative of a number of cyclin D1-responsive promoters
(Supplemental Data, Section 9). Results are means SD of three independent experiments each with triplicate determinations.
(E) Dominant-negative C/EBP renders promoters refractory to cyclin D1. MCF-7 cells were cotransfected with a reporter construct, a fixed
amount of a cyclin D1-KE expression plasmid, or an empty vector, and different amounts of a plasmid directing the expression of C/EBPSpl.
Normalized promoter activity was determined 24 hr later and fold increases in promoter activity relative to empty vector induced by cyclin
D1-KE at each level of C/EBPSpl were calculated. Data shown are for the HSC70 promoter (code 101) but are qualitatively representative
of a number of cyclin D1-responsive promoters (Supplemental Data, Section 10). Results are means  SD of three independent experiments,
each with triplicate determinations.
(F) C/EBP nullizygousity renders the HSP70-2 promoter refractory to cyclin D1. Mammary epithelial cells derived from wild-type (SCp2) or
C/EBP/ mice were cotransfected with an HSP70-2 reporter construct (code 140) or its mutant counterpart (code 121) and either an empty
vector or a plasmid directing the expression of cyclin D1. Normalized promoter activity was determined 30 hr later and fold increases in
promoter activity induced by cyclin D1 relative to empty vector for each reporter in each cell line were calculated. Results are means  SD
of three independent experiments, each with triplicate determinations.
(G) Mutation of the asparagine synthetase promoter abolishes cyclin D1 responsiveness. MCF-7 cells were cotransfected with either a wild-
type (code 106) or mutant (code 122) reporter construct and an empty vector or plasmids directing expression of cyclin D1 or cyclin D1-KE.
Normalized luciferase activities were determined 24 hr later, and fold increases in promoter activity relative to empty vector for each reporter
were calculated. Results are means SD of three independent experiments, each with triplicate determinations.
(H) Physical interaction of cyclin D1 and C/EBP. MCF-7 cells were cotransfected as indicated. Twenty-four hours later, whole-cell lysates
were prepared and complex formation assessed by immunoprecipitation with antibodies directed against C/EBP, the FLAG-epitope, E1A,
or normal rabbit serum (NRS), followed by immunoblotting with anti-HA antibody. The relative amounts of cyclin D1-HA, C/EBP, and
C/EBP-FLAG present in whole-cell lysates (WCL) were assessed with the same antibodies.
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prepared as described (He et al., 1998). Ad-GFP was a gift from across the entire panel was less than 100. The remaining 6,471
genes were ordered according to the Euclidean distance of theKornelia Polyak. MCF-7 cells were cultured in DMEM supplemented
with 10% fetal bovine serum (FBS) and infected with adenoviruses vector of their expression pattern across all specimens from that
of cyclin D1 (X59798) or cyclin D3 (M92287).at a multiplicity of infection of 10. Total RNA was isolated at various
times thereafter using TRIzol Reagent (Invitrogen). SCp2 cells were The distribution of the each target gene set within the ordered
lists of genes from the GCM was measured using the Kolmogorov-a gift from Mina Bissell (Desprez et al., 1993). The C/EBP-deficient
mammary epithelial cell line was established from the isolated mam- Smirnov nonparametric rank statistic (Hollander and Wolfe, 1999).
Cyclin D1 or cyclin D3 was removed from the ordered lists, givingmary glands of mature virgin outbred C/EBP nullizygous mice
(Screpanti et al., 1995) as described (Kittrell et al., 1992). A luminal two lists of 6,470 genes. Let X be the number of genes in a target
gene set. X  21 and X  22 for the cyclin D1 and E2F target geneepithelial origin was confirmed by the expression of luminal cytoker-
atins. Both murine lines were cultured in HEPES buffered DMEM-F12 sets, respectively. Set Y  6470  Y and construct a vector V where
V(i) is the component corresponding to gene i. Set V(i)  Y if i issupplemented with 2% FBS, 5 	g/ml insulin, and 5 ng/ml epidermal
growth factor. in the target gene set and V(i)  X if not. Thus,

6470
i1
V(i)  0.Microarrays
Synthesis of cRNA, its hybridization to microarrays (Affymetrix Gene-
Chip Hu6800), and array scanning were as described (Golub et al., Our statistic S (“KS score”) is the maximum value of the running
1999). Intensity values were scaled such that the overall fluores- sum of consecutive values of V defined as
cence intensity of each microarray was equivalent. Expression val-
ues below baseline (100) were set to 100. Expression levels for max
j

j
i1
V(i).
each gene were normalized within each independent experiment
by setting the mean to 0 and standard deviation to 1. Raw gene The significance of S was tested by permutation. For 100,000 trials,
expression data are available at www-genome.wi.mit.edu/cancer/ we chose X genes at random from the set of 6,470 and counted
pub/cyclin_d1. how often the statistic on our actual data set was equaled or ex-
ceeded. The frequency of this event can be taken as a P value.
Gene Selection
Two methods were used. For Method A, genes were selected on Kolmogorov-Smirnov Scanning (KSS)
the following criteria: (1) expression level at any point more than Each gene in a database of interest was used as a prototype. The
4 hr after infection was greater than 3-fold above that in the unin- remaining genes were ordered by the Euclidean distance of the
fected time-zero control, in both independent experiments; (2) fold vector of their expression pattern from that of the prototype gene,
change at a timepoint adjacent to the maximum was at least 2% and a KS score computed for each with the cyclin D1 target gene
and no less than 50% of the peak value in each experiment, or the set, as above. Genes were then ranked by their KS score. The
expression maximum was at the 24 hr timepoint in both experiments. process is represented schematically as Figure 4A.
Genes whose expression characteristics after transduction of GFP
also fulfilled these criteria were then excluded. For Method B, the ten Promoter Analysis
genes whose normalized expression vectors from both independent Promoter fragments were recovered from genomic DNA, BAC
experiments were separated by the shortest Euclidean distances clones, or plasmid templates by PCR with primers containing syn-
from that of HSP70-2 (M59830), after those whose expression level thetic recombination sites and introduced upstream of the luciferase
varied less than 2-fold in either of the two experiments had been reporter gene in a modified pGL3-basic (Promega) using Gateway
masked, were selected. cloning technology (Invitrogen). Point mutations were introduced
by two-step PCR. Constructs were confirmed by sequencing. Chro-
Ribonuclease Protection Assays mosome coordinates of the promoter fragments and details of the
Radiolabeled antisense riboprobes were prepared using Lig’nScribe mutations introduced are provided as Supplemental Data, Section 7.
and MAXIscript in vitro transcription kits (Ambion). Multiplexed ribo- Cyclin D1 expression plasmids (pRc/CMV-cyclin D1-HA, pRc/CMV-
nuclease protection assays were performed with RPAIII (Ambion) cyclin D1-KE-HA) are described (Neuman et al., 1997). Expression
in accordance with the manufacturer’s instructions. Sequences of plasmids for C/EBP, and a C/EBPmutant resulting from the dele-
riboprobe templates are available upon request. tion of an internal in-frame SplI fragment encoding amino acids between
41 and 205 (Tsukada et al., 1994) (pcDNA3.1-C/EBP, pcDNA3.1-C/
Human Tumor Gene Expression Databases EBPSpl) were gifts from Philip Auron. Cells were transfected with
Gene expression data from the Global Cancer Map (GCM; 190 speci- the indicated constructs together with a -galactosidase expression
mens, 16,063 genes, Affymetrix GeneChip Hu6800 and Hu35KsubA) plasmid, as internal control, using Superfect Reagent (Qiagen) or
(Ramaswamy et al., 2001), and from prostate (52 specimens, 12,600 FuGENE 6 (Roche) for MCF-7 and murine epithelial cells, respec-
genes, GeneChip U95Av2) (Singh et al., 2002), lung (186 specimens, tively. Luciferase and -galactosidase activities were assayed
12,600 genes, U95Av2) (Bhattacharjee et al., 2001), and brain (86 (Lamb et al., 2000) and normalized promoter activity calculated.
specimens, 7129 genes, Hu6800) (Pomeroy et al., 2002) tumor col-
lections, and the cell lines of the NCI60 (60 specimens, 7129 genes, Electrophoretic Mobility Shift Assay
Hu6800) (Staunton et al., 2001) were downloaded from www-genome. Cells were incubated on ice for 5 min in lysis buffer (10 mM tris-
wi.mit.edu/cgi-bin/cancer/datasets.cgi. Scaling was as adopted by HCl [pH 8.0], 60 mM KCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, 0.3%
the authors of the original studies. Data from normal samples in- NP-40). Nuclei were recovered by gentle centrifugation, washed in
cluded in a number of these collections were discarded. Expression lysis buffer without NP-40, and incubated on ice for 10 min in extrac-
values below baseline (20) were set to 20. Expression levels for each tion buffer (20 mM tris-HCl [pH 8.0], 400 mM NaCl, 1.5 mM MgCl2,
gene across all specimens within a given database were normalized 0.2 mM EDTA, 25% glycerol). Nuclear extracts were cleared by
by setting the mean to 0 and standard deviation to 1. centrifugation at 14,000 rpm. A synthetic double-stranded DNA
probe containing a cyclin D1-response element (underlined) (sense-
strand, 5-GCA GAT TCT GGA AAG TTC TGA-3) was end-labeledKolmogorov-Smirnov Analysis
The cyclin D1 target gene set was from Figure 2. E2F target genes with [
-32P]ATP (New England Nuclear) and T4 polynucleotide kinase
(New England Biolabs). Ten micrograms of nuclear extract was incu-were defined by the human UniGene clusters (build 139) correspond-
ing to the mouse UniGene identifiers (build 95) associated with the bated with an equal volume of binding buffer (10 mM tris-HCl [pH
7.5], 50 mM NaCl, 0.5 mM EDTA, 0.5 mM DTT, 1 mM MgCl2, 4%accession numbers reported by Ishida et al. (2001), according to
HomoloGene (November 5, 2001 version). The subset of genes in glycerol, 200 	g/ml salmon sperm DNA) on ice for 15 min. One
nanogram of radiolabeled probe was added, together with a fifty-the GCM whose levels were not determined using Hu6800 microar-
rays was masked, as were those genes whose expression level fold molar excess of unlabeled competitor oligonucleotide duplexes
(Supplemental Data, Section 8) as indicated, and incubation contin-varied less than 3-fold or where the range of expression values
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ued for 10 min at room temperature. Two microliters of antibody Dyson, N. (1998). The regulation of E2F by pRb-family proteins.
Genes Dev. 12, 2245–2262.against C/EBP (sc-150X) or STAT3 (sc-482X) (Santa Cruz Biotech-
nology) was added where indicated, and incubation continued for Gaugitsch, H.W., Prieschl, E.E., Kalthoff, F., Huber, N.E., and Baum-
an additional 10 min at room temperature. Protein-DNA complexes ruker, T. (1992). A novel transiently expressed, integral membrane
were resolved through nondenaturing polyacrylamide gels. protein linked to cell activation. Molecular cloning via the rapid
degradation signal AUUUA. J. Biol. Chem. 267, 11267–11273.
Immunoprecipitation Golub, T.R., Slonim, D.K., Tamayo, P., Huard, C., Gaasenbeek, M.,
Cells were transfected with pRc/CMV-cyclin D1-HA, pcDNA3.1-C/ Mesirov, J.P., Coller, H., Loh, M.L., Downing, J.R., Calgiuri, M.A., et
EBP, a plasmid directing expression of C/EBP (pcDNA3-C/ al. (1999). Molecular classification of cancer: Class discovery and
EBP-FLAG; a gift from Daniel Tenen), or an empty vector, as indi- class prediction by gene expression monitoring. Science 286,
cated, using Superfect Reagent (Qiagen). Immunoprecipitations and 531–537.
immunoblotting were performed as described (Lamb et al., 2000) Hall, M., and Peters, G. (1996). Genetic alterations of cyclins, cyclin-
using antibodies against the FLAG-epitope (M2) (Sigma-Aldrich) or dependent kinases, and cdk inhibitors in human cancer. Adv. Cancer
E1A (M73) as an irrelevant control, C/EBP (sc-150) (Santa Cruz Res. 68, 67–108.
Biotechnology) or normal rabbit serum, and the HA-epitope (12CA5).
He, T.-C., Zhou, S., da Costa, L.T., Yu, J., Kinzler, K.W., and Vo-
gelstein, B. (1998). A simplified system for generating recombinant
Supplemental Data adenoviruses. Proc. Natl. Acad. Sci. USA 95, 2509–2514.
All Supplemental Data can be found at http://www.cell.com/cgi/
Hinds, P.W., Dowdy, S.F., Eaton, E.N., Arnold, A., and Weinberg,content/full/114/3/323/DC1.
R.A. (1994). Function of a human cyclin gene as an oncogene. Proc.
Natl. Acad. Sci. USA 91, 709–713.
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